Clinical Trial Update: Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing safety and protective effect of GSK's HPV vaccine (types 16/18) in healthy females; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia

Drugs mentioned

• GSK580299 (HPV vaccine, adsorbed, types 16 and 18) (HPV vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cervical Intraepithelial Neoplasia | Phase 4 | Status: COMPLETED | Results posted: 2020-12-19